Supernus Pharmaceuticals Inc
SUPN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.48B
Close$
$72.92
65.8% upside
Current Fair Value
65.8% upsideUndervalued by 65.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.48 Billion |
|---|---|
| Enterprise Value | $2.34 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.68 |
| Beta | 0.56 |
| Outstanding Shares | 58,070,000 |
Return
| Return on Equity | -10.66% |
|---|---|
| Return on Assets | -7.69% |
| Return on Invested Capital | -13.85% |
Valuation & Multiples
| P/E Ratio | -22.2 |
|---|---|
| PEG | 6.18 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 2.59 |
| Enterprise Value to Revenue | 0.01 |
| Enterprise Value to EBIT | -15.61 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.42
Average shareholder expectationRevenue Estimate
$205.31 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.61
Average shareholder expectationRevenue Estimate
$218.29 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 6.4252▲ 476.88% |
|---|---|
| Total Calls | 20,871▼ 67.17% |
| Total Puts | 134,100▲ 27.35% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.03%▲ 4.02% |
|---|---|
| Total Invested | $2.83B▼ 5.79% |
| Investors Holding | 340▲ 5.00% |
ESG Score
No data
About Supernus Pharmaceuticals Inc
CEO: Jack Khattar